2 0 0 0 OA A review of EBV-positive mucocutaneous ulcers focusing on clinical and pathological aspects
- 著者
- Tomoka Ikeda Yuka Gion Tadashi Yoshino Yasuharu Sato
- 出版者
- The Japanese Society for Lymphoreticular Tissue Research
- 雑誌
- Journal of Clinical and Experimental Hematopathology (ISSN:13464280)
- 巻号頁・発行日
- vol.59, no.2, pp.64-71, 2019 (Released:2019-06-28)
- 参考文献数
- 53
- 被引用文献数
- 23 61
Epstein-Barr virus (EBV)-positive mucocutaneous ulcers (EBVMCUs) were first described as a lymphoproliferative disorder in 2010. Clinically, EBVMCUs are shallow, sharply circumscribed, unifocal mucosal or cutaneous ulcers that occur in immunosuppressed patients, including those with advanced age-associated immunosenescence, iatrogenic immunosuppression, primary immune disorders, and HIV/AIDS-associated immune deficiencies. In general, patients exhibit indolent disease progression and spontaneous regression. Histologically, EBVMCUs are characterized by the proliferation of EBV-positive, variable-sized, atypical B-cells. According to conventional histopathologic criteria, EBVMCUs may diagnosed as lymphomas. However, EBVMCUs are recognized as pseudomalignant lesions because they spontaneously regress without anti-cancer treatment. Therefore, overtreatment must be carefully avoided and multilateral differentiation is important. In this article, we reviewed previously reported EBVMCUs focusing on their clinical and pathological aspects in comparison with other EBV-positive B-cell neoplasms.
1 0 0 0 OA Hemosiderin deposition in lymph nodes of patients with plasma cell-type Castleman disease
- 著者
- Yanyan Han Takuro Igawa Kyohei Ogino Asami Nishikori Yuka Gion Tadashi Yoshino Yasuharu Sato
- 出版者
- The Japanese Society for Lymphoreticular Tissue Research
- 雑誌
- Journal of Clinical and Experimental Hematopathology (ISSN:13464280)
- 巻号頁・発行日
- pp.19037, (Released:2020-02-08)
- 参考文献数
- 20
- 被引用文献数
- 9
Plasma cell-type Castleman disease (PCD) is a rare idiopathic atypical lymphoproliferative disorder. It is difficult to differentiate between PCD and IgG4-related disease (IgG4-RD) based on histology alone. As PCD often presents with abundant hemosiderin deposition, lymph node lesions obtained from 22 PCD patients and 12 IgG4-RD patients were analyzed using Prussian blue staining to clarify whether hemosiderin deposition is effective in distinguishing between these two diseases. The analysis disclosed that hemosiderin was more densely deposited in PCD than in IgG4-RD. The median number of Prussian blue-positive cells ± standard deviation (SD) in PCD and IgG4-RD cases was 13 ± 36 cells/3HPFs and 4 ± 8 cells/3HPFs (P = 0.034), respectively. In addition, we analyzed the relationship between hemosiderin deposition and levels of serum interleukin (IL)-6, serum C-reactive protein (CRP), and anemia-related biomarkers. We found that hemosiderin deposition was significantly correlated with the level of serum CRP (P = 0.045); however, no significant correlation was observed between hemosiderin deposition and serum IL-6 levels (P = 0.204). A non-significant positive correlation was observed between hemosiderin deposition and serum hemoglobin levels (P=0.09). Furthermore, no significant correlation was observed between hemosiderin deposition and serum iron levels (P = 0.799). In conclusion, hemosiderin deposition characteristically observed in PCD may be related to the inflammatory aggressiveness of the disease and could be used for its differential diagnosis.